English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/49718
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Targeting a marker of the tumour neovasculature using a novel anti-human CD105-immunotoxin containing the non-toxic type 2 ribosome-inactivating protein nigrin b.

AuthorsMuñoz, Raquel; Arias, Yolanda; Ferreras, José M.; Rojo, María A.; Gayoso, Manuel J.; Nocito, Mercedes; Benitez, Jorge; Jimenez, Pilar; Bernabéu, Carmelo ; Girbes, Tomás
KeywordsNigrin b
Endoglin
Anti-endoglin antibody
Transfectant hCD105 cells
Anti-tumour therapy
Issue Date18-Oct-2007
PublisherElsevier
CitationCancer Letters 256:73-80(2007)
AbstractTargeting tumour neovasculature using antibodies to the endothelial receptor CD105 (endoglin), is a potentially useful approach for anti-tumour therapy. We report on the preparation and the cytotoxicity of a novel immunotoxin consisting in the non-toxic type 2 ribosome-inactivating protein (RIP) nigrin b linked to the monoclonal anti-human CD105 (hCD105) antibody 44G4. The immunotoxin kills specifically mouse fibroblasts expressing the biomarker CD105 (L929-hCD105+ cells) with an IC50 value of 6 × 10−10 M while nigrin b does it at 2.4 × 10−7 M. Immunofluorescence analysis indicated that the immunotoxin accumulates in a perinuclear region. In contrast, 44G4 showed a specific localization on the cell surface
Description8 páginas, 4 figuras -- PAGS nros. 73-80
Publisher version (URL)http://dx.doi.org/10.1016/j.canlet.2007.05.012
URIhttp://hdl.handle.net/10261/49718
DOI10.1016/j.canlet.2007.05.012
ISSN0304-3835
E-ISSN1872-7980
Appears in Collections:(CIB) Artículos
Files in This Item:
There are no files associated with this item.
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.